Skip to main content
Premium Trial:

Request an Annual Quote

Novacyt Acquires Instrument Manufacturer IT-IS for £10.1M

NEW YORK ─ Novacyt on Thursday announced the acquisition of IT-IS International, the exclusive manufacturer of its q16 and q32 rapid PCR instruments.

Paris-based Novacyt will pay £10.1 million ($13.1 million) in cash upfront for the issued share capital of IT-IS and business assets of IT-IS Life Science (Ireland).

The acquisition of Stokesley, UK-based IT-IS, a private diagnostic instrument development and manufacturing company founded in 2004, secures important intellectual property for its q16 and q32 rapid-PCR instruments for near-patient testing of COVID-19, Novacyt said. The acquisition further expands its core capabilities in instrument manufacturing and product offerings in mobile PCR devices, the firm added.

"IT-IS has established a reputation as experts in the development of mobile and rapid PCR instruments," Graham Mullis, group CEO of Novacyt, said in a statement. "This acquisition ensures that Novacyt is in a strong position to fulfill the growing market demands for rapid near-patient testing of COVID-19, as well as other infectious diseases."

Novacyt said that as a result of this acquisition, it will become a diagnostic platform instrument and reagent manufacturer and will significantly increase the manufacturing capability of IT-IS to manage the expected demand for its q16 and q32 PCR instruments.

As a result of higher manufacturing volume, Novacyt expects to reduce its cost of goods and therefore improve the gross margin of its instrument sales.

Novacyt added that the COVID-19 pandemic presents it with a significant opportunity to place rapid mobile testing instruments as shortages in testing capacity and limitations of laboratory-based testing drives healthcare away from large centralized platforms.

The acquisition of IT-IS includes customers, suppliers, software, patents, trademarks, contracts, stocks, technical files, and know-how to design, manufacture, distribute, and market IT-IS's commercial product portfolio. The product portfolio includes IT-IS-branded MyGo Mini and MyGo Pro PCR instruments.

Novacyt said that the acquisition is immediately accretive to earnings. IT-IS posted revenues of £3.9 million and a net profit of £800,000 for fiscal year 2019, and revenues are expected to increase to £5.0 million for fiscal year 2020.

The Scan

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.

Tumor Microenvironment Immune Score Provides Immunotherapy Response, Prognostic Insights

Using multiple in situ analyses and RNA sequence data, researchers in eBioMedicine have developed a score associated with immunotherapy response or survival.

CRISPR-Based Method for Finding Cancer-Associated Exosomal MicroRNAs in Blood

A team from China presents in ACS Sensors a liposome-mediated membrane fusion strategy for detecting miRNAs carried in exosomes in the blood with a CRISPR-mediated reporter system.

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.